首页
订购/客服:400-666-5481

DRF-1042

    
≥98%

DRF-1042

源叶(MedMol)
S89553 一键复制产品信息
200619-13-2
C22H20N2O6
408.404
5-(2'-Hydroxyethoxy)-20(S)-camptothecin; UNII-461WVF206P; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione,4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-,(4S);
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
S89553-1mg促销
≥98%

¥280.00 ¥252.00

6 - - - -
S89553-5mg促销
≥98%

¥660.00 ¥594.00

4 - - - -
S89553-10mg促销
≥98%

¥1070.00 ¥962.00

2 - - - -
S89553-50mg促销
≥98%

¥3520.00 ¥3160.00

1 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype
靶点: DNA topoisomerase I
体外研究: DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype
体内研究: In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies
参考文献: 1. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. 2. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
溶解性: Soluble  in  DMSO
保存条件: 2-8℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 2.449 ml 12.243 ml 24.486 ml
5 mM 0.49 ml 2.449 ml 4.897 ml
10 mM 0.245 ml 1.224 ml 2.449 ml
50 mM 0.049 ml 0.245 ml 0.49 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×